Co-Authors
This is a "connection" page, showing publications co-authored by Alexis Mathian and Zahir Amoura.
Connection Strength
15.332
-
Response to: 'Antirheumatic drugs, B cell depletion and critical COVID-19: correspondence on 'Clinical course of coronavirus disease 2019 (COVID-19) in a series of 17 patients with systemic lupus erythematosus under long-term treatment with hydroxychloroquine by Mathian et al' by Notz et al. Ann Rheum Dis. 2020 Nov 25.
Score: 0.915
-
Response to: 'Implications of SARS-CoV-2 infection for patients with rheumatic disease' by Lin et al. Ann Rheum Dis. 2020 Sep 07.
Score: 0.902
-
Response to 'Impact of COVID-19 pandemic on hospitalisation of patients with systemic lupus erythematosus (SLE): report from a tertiary hospital during the peak of the pandemic' by Chuah et al. Ann Rheum Dis. 2020 Sep 03.
Score: 0.901
-
Response to: 'Exacerbation of immune thrombocytopenia triggered by COVID-19 in patients with systemic lupus erythematosus' by Kondo et al. Ann Rheum Dis. 2021 05; 80(5):e78.
Score: 0.896
-
Response to: 'Presence of anti-phospholipid antibodies in COVID-19: a case series study' by Amezcua-Guerra et al. Ann Rheum Dis. 2021 05; 80(5):e74.
Score: 0.896
-
Response to: 'COVID-19 among Malaysian patients with systemic lupus erythematosus on hydroxychloroquine' by Teh et al. Ann Rheum Dis. 2021 05; 80(5):e70.
Score: 0.895
-
Response to: 'Impact of COVID-19 pandemic on patients with SLE: results of a large multicentric survey from India' by Goyal et al. Ann Rheum Dis. 2021 05; 80(5):e72.
Score: 0.892
-
Response to: 'Concerns and needs of patients with systemic lupus erythematosus regarding hydroxychloroquine supplies during the COVID-19 pandemic: results from a patient-centred survey' by Plüß et al. Ann Rheum Dis. 2020 Jul 02.
Score: 0.890
-
Response to: 'Monitoring of patients with systemic lupus erythematosus during the COVID-19 outbreak' by Holubar et al. Ann Rheum Dis. 2020 Jun 08.
Score: 0.886
-
Response to: 'Patients with lupus with COVID-19: University of Michigan experience' by Wallace et al. Ann Rheum Dis. 2020 May 31.
Score: 0.885
-
Response to: Correspondence regarding research letter to the editor by Mathian et al, 'Clinical course of coronavirus disease 2019 (COVID-19) in a series of 17 patients with systemic lupus under long-term treatment with hydroxychloroquine'' by Nikpour et al. Ann Rheum Dis. 2020 May 29.
Score: 0.884
-
Response to: 'Are patients with systemic lupus erythematosus at increased risk for COVID-19?' by Favalli et al. Ann Rheum Dis. 2021 02; 80(2):e26.
Score: 0.884
-
Clinical course of coronavirus disease 2019 (COVID-19) in a series of 17 patients with systemic lupus erythematosus under long-term treatment with hydroxychloroquine. Ann Rheum Dis. 2020 06; 79(6):837-839.
Score: 0.879
-
Lupus and vaccinations. Curr Opin Rheumatol. 2018 09; 30(5):465-470.
Score: 0.784
-
Clarkson's Disease Episode or Secondary Systemic Capillary Leak-Syndrome: That Is the Question! Chest. 2021 01; 159(1):441.
Score: 0.230
-
COVID-19-associated collapsing glomerulopathy: a report of two cases and literature review. Intern Med J. 2020 12; 50(12):1551-1558.
Score: 0.229
-
Safety and effectiveness of transjugular renal biopsy for systemic lupus erythematosus and antiphospholipid antibody syndrome patients taking antithrombotics. Nephrol Dial Transplant. 2020 10 01; 35(10):1721-1729.
Score: 0.226
-
Achieving lupus low-disease activity and remission states under belimumab in refractory systemic lupus erythematosus: time and organ involvement matter. Ann Rheum Dis. 2020 11; 79(11):e148.
Score: 0.208
-
Clinical, histological, immunological presentations and outcomes of bullous systemic lupus erythematosus: 10 New cases and a literature review of 118 cases. Semin Arthritis Rheum. 2018 08; 48(1):83-89.
Score: 0.185
-
Renal effects of immune checkpoint inhibitors. Nephrol Dial Transplant. 2017 Jun 01; 32(6):936-942.
Score: 0.180
-
Clinicopathological features of multiple mononeuropathy associated with systemic lupus erythematosus: a multicenter study. J Neurol. 2017 Jun; 264(6):1218-1226.
Score: 0.179
-
Successful outcome of proliferative lupus nephritis during pregnancy: Toward a modern paradigm of lupus pregnancy? Eur J Obstet Gynecol Reprod Biol. 2017 Jul; 214:201-203.
Score: 0.179
-
Long-term outcomes of refractory neurosarcoidosis treated with infliximab. J Neurol. 2017 May; 264(5):891-897.
Score: 0.177
-
Cardiac adipose tissue volume and IL-6 level at admission are complementary predictors of severity and short-term mortality in COVID-19 diabetic patients. Cardiovasc Diabetol. 2021 08 12; 20(1):165.
Score: 0.060
-
Evolution of Nutritional Status after Early Nutritional Management in COVID-19 Hospitalized Patients. Nutrients. 2021 Jun 30; 13(7).
Score: 0.060
-
Distinct cytokine profiles associated with COVID-19 severity and mortality. J Allergy Clin Immunol. 2021 06; 147(6):2098-2107.
Score: 0.059
-
The spectrum of kidney biopsies in hospitalized patients with COVID-19, acute kidney injury, and/or proteinuria. Nephrol Dial Transplant. 2021 Feb 12.
Score: 0.058
-
IgA dominates the early neutralizing antibody response to SARS-CoV-2. Sci Transl Med. 2021 01 20; 13(577).
Score: 0.057
-
Correspondence on 'Glucocorticoid-induced relapse of COVID-19 in a patient with sarcoidosis'. Ann Rheum Dis. 2020 Oct 01.
Score: 0.057
-
Prevalence and severity of malnutrition in hospitalized COVID-19 patients. Clin Nutr ESPEN. 2020 12; 40:214-219.
Score: 0.056
-
Response to Letter: 'Reply to "High frequency of antiphospholipid antibodies in critically ill COVID-19 patients: a link with hypercoagulability?"'. J Intern Med. 2021 03; 289(3):427-429.
Score: 0.056
-
Coronavirus Disease 2019 Acute Myocarditis and Multisystem Inflammatory Syndrome in Adult Intensive and Cardiac Care Units. Chest. 2021 02; 159(2):657-662.
Score: 0.056
-
High frequency of antiphospholipid antibodies in critically ill COVID-19 patients: a link with hypercoagulability? J Intern Med. 2021 03; 289(3):422-424.
Score: 0.056
-
CAPS criteria fail to identify most severely-ill thrombotic antiphospholipid syndrome patients requiring intensive care unit admission. J Autoimmun. 2019 09; 103:102292.
Score: 0.052
-
Infliximab biosimilar for treating neurosarcoidosis: tolerance and efficacy in a retrospective study including switch from the originator and initiation of treatment. J Neurol. 2019 May; 266(5):1073-1078.
Score: 0.051
-
Synergistic convergence of microbiota-specific systemic IgG and secretory IgA. J Allergy Clin Immunol. 2019 04; 143(4):1575-1585.e4.
Score: 0.050
-
Renal toxicities associated with pembrolizumab. Clin Kidney J. 2019 Feb; 12(1):81-88.
Score: 0.050
-
Microbial ecology perturbation in human IgA deficiency. Sci Transl Med. 2018 05 02; 10(439).
Score: 0.048
-
Symptomatic muscular sarcoidosis: Lessons from a nationwide multicenter study. Neurol Neuroimmunol Neuroinflamm. 2018 May; 5(3):e452.
Score: 0.047
-
Efficacy and safety of biologics in relapsing polychondritis: a French national multicentre study. Ann Rheum Dis. 2018 08; 77(8):1172-1178.
Score: 0.047
-
Myocardial dysfunction is frequent in systemic capillary-leak syndrome (Clarkson disease) severe episodes. J Allergy Clin Immunol. 2018 04; 141(4):1539-1540.
Score: 0.047
-
Inclusion body myositis and human immunodeficiency virus type 1: A new case report and literature review. Neuromuscul Disord. 2018 04; 28(4):334-338.
Score: 0.047
-
[Cancers associated with systemic sclerosis involving anti-RNA polymerase III antibodies]. Ann Dermatol Venereol. 2018 Jan; 145(1):33-36.
Score: 0.046
-
Clinical spectrum and therapeutic management of systemic lupus erythematosus-associated macrophage activation syndrome: A study of 103 episodes in 89 adult patients. Autoimmun Rev. 2017 Jul; 16(7):743-749.
Score: 0.045
-
International and multidisciplinary expert recommendations for the use of biologics in systemic lupus erythematosus. Autoimmun Rev. 2017 Jun; 16(6):650-657.
Score: 0.045